Default company panoramic image

Replicor Inc.

Developing the cure for 400 million patients with chronic hepatitis B

  • Stage Concept Only
  • Industry Biotechnology
  • Location Montreal, QC, Canada
  • Currency USD
  • Website

Company Summary

Replicor, a biopharmaceutical company, is developing a new drug that will revolutionize the treatment of patients with chronic hepatitis B. There are 400 million patients with chronic hepatitis B in the world. Current therapies rarely achieve a cure. Our drug allows the re-establishment of a proper immune response to the infection. The efficacy and safety of our drug has already been successfully demonstrated in ongoing human clinical trials.


  • Default avatar
    Michel Bazinet
    Chairman & CEO

    See our website for our team members and Bio.